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Acquired immunodeficiency syndrome was first. rec­
ognized as a new disease in 1981 because of the unusual 
association of Kaposi's sarcoma and Pneumocystis carinii 
pneumonia in young men. The skin remains one of the 
most important clinical markers for acquired immuno­
deficiency syndrome, now recognized as the end stage 
of infection with the human immunodeficiency virus 
(IflV). Indeed, an urticarial viral exanthem appearing 
during seroconversion may allow early identification of 
newly infected individuals who might benefit from 
administration of antiviral therapy during plasma vire­
mia. The "asymptomatic HIV infection" is often ac­
companied by multiple skin complaints, which com­
monly include xerosis, pruritus, psoriasis/seborrheic 
dermatitis, and pruritic papular eruptions, the cause of 
C utaneous manifestations appear at different stages of immunodeficiency; some are prognostic markers for disease progression. The Walter Reed system [1] separates human immunodeficiency virus (HIV) infection into six classifications based on the symp­
toms, infections, and CD4 count, the final stage being acquired 
immunodeficiency syndrome (AIDS) (Table I) [2]. The diagnosis 
of AIDS has been expanded to include patients with CD4 T-cell 
counts less than 200 cells/mm3, regardless of opportunistic infec­
tions. As the full spectrum of HIV infection has been appreciated, 
the term "cutaneous manifestation" encompasses everything from 
primary HIV seroconversion reaction to the opportunistic infec­
tions of end-stage immunodeficiency. Several interesting contro­
versial manifestations, their etiology, and relation to HIV infection 
are selected for discussion. 
THE SKIN AS THE FIRST TARGET FOR HIV INFECTION 
The mucous membranes, which lack the protective stratum cor­
neum, are rich in bone-marrow-derived Langerhans cells express­
ing CD4+, the HIV receptor [3,4]. Langerhans cells were the first 
skin cell demonstrated to be infected with HIV and can transmit it 
to T cells in culture [5,6]. Other skin cells, including fibroblasts, 
which lack CD4, are able to be infected with HIV, and epithelial 
cells are infected by cell-to-cell entry via macrophages [6]. Epide­
miologic evidence supports mucosal transmission. Females are 
more easily infected by intercourse than are males. In African 
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which remains controversial. Psoriasis and Kaposi's 
sarcoma lesions share features including angiogenesis, 
dermal dendrocytes infected with HIV, and epidermal 
hyperproliferation, and are manifested by mice trans­
genic for HIV provirus or Tat-Itr. Changes in the 
immune system including T-cell function, antigen re­
sponse, and shifting cytokine expression as well as a 
propensity for autoimmune reactions must underlie the 
skin immunodysfunction occurring in the setting of 
HIV infection. One of the most unsettling controver­
sies suggested by in vitro data is that ultraviolet light, an 
effective therapy for HIV -related skin disorders, may 
actually activate the virus. Key words: cutaneous manifes­
tations/psoriasis/Kaposi's sarcoma/pruritus. ] Invest Dermatol 
105:1178-1218, 1995 
males, infection rates reflect the absence of circumcision and the 
presence of genital ulcers [7]. The minimum viral inoculum capable 
of infecting via mucous membrane or skin exposure is unknown. 
THE SKIN IN PRIMARY HIV INFECTION 
SEROCONVERSION REACTION 
Seroconversion follows HIV inoculation in several weeks to 
months, or possibly years [8]. Whether the duration of the asymp­
tomatic period is determined by the route of infection, strain or 
number of virus transmitted, or host response is not known. 
Individuals with T-cell immunity to mv proteins without serocon­
version or apparent infection have been reported [9]. The signifi­
cance of aT-cell reaction to HIV peptides without seroconversion 
is unclear, although it suggests that exposure to minuscule amounts 
or to noninfectious virus has occurred. Whether these individuals 
have undetectable infection and will later seroconvert or whether 
they are now immune to HIV infection is a question of great 
interest and importance. 
Seroconversion involves a mononucleosis-like illness with fever, 
malaise, pharyngitis, and headache resulting from viremia [10,11]. 
In up to 70% of patients who are identified with primary HIV 
infection, a rash is present, which is an urticarial, morbilliform, or 
macular exanthem similar to that of other viruses. Lesions may 
measure up to 1 em and occur most often on the trunk, sparing the 
face and extremities. Virus has not yet been documented as present 
in the lesions. Mouth ulcers, common in the seroconversion 
reaction, distinguish HIV from mononucleosis [12]. The diagnosis 
of acute HIV seroconversion requires demonstration of p24 or viral 
culture until antibody titers rise to detectable levels. It is now 
appreciated that the immune system begins to deteriorate at the 
time of seroconversion and that HIV infection is a chronic disease. 
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Table I. Cutaneous Manifestations of HIV Infection 





















Viral replication occurs primarily within the lymph nodes, and 
newly synthesized CD4+ cells are infected [13,14]. Early admin­
istration of antiviral therapy at the time of seroconversion might 
change the time to immunodeficiency . 
THE SKIN IN EARLY HIV INFECTION 
The first symptoms ofHIV infection involve the skin [15,16] and 
increase as the immune system deteriorates [17]. Mucosal candidi­
asis was found most commonly with HIV infection, especially in 
patients with established immunodeficiency [18] . Xerosis to the 
point of acquired ichthyosis is associated with either early or late 
HIV infection [19,20]. Ichthyosis is also associated with Hodgkin's 
disease, carcinoma, autoimmune disease, and atopic dermatitis. In 
the clinical setting, pruritus and atopy with or without xerosis are 
common and unrelenting problems of HIV -infected persons, and 
they have been referred to as the pruritic papular syndrome [21-23]. 
THE PRURITIC PAPULAR SYNDROME 
James et al [24] described a papular rash with a perifollicular 
infiltrate attributed to HIV infection in the skin. HIV has been 
identified in involved skin [25]. Pruritus was also described early on 
as a sign of HIV infection [23,26]. Duvic suggested a "papular­
pruritus-folliculitis syndrome" requiring a differential diagnosis 
including staphylococcal folliculitis, scabies, and demodex follicu­
litis [27] . The presence of demodex folliculitis in AIDS was also 
suggested by Ashack et al [28] and Dominey et al [29]. Granuloma 
annularis is also included in the differential diagnosis . 
Eosinophilic folliculitis describes a condition characterized by 
flesh-colored papules on the trunk that are intensely pruritic 
[30,31]. Histopathologic studies have shown perifollicular eosi­
nophils, prominent dermal dendritic cells, atypical vascular prolif­
eration, and dermal fibrosis in biopsy specimens [31-33]. Patients 
with eosinophilic folliculitis may also have elevated 19B levels [34] 
and hypersensitivity to mosquito saliva antigens [35]. Eosinophilic 
folliculitis is a late manifestation of HIV infection in persons with 
CD4 counts less than 200 cells/mm3 and therefore may be a 
predictive marker for those at risk for opportunistic infections [34]. 
Treatment of the pruritic papular syndrome has been disappoint­
ing. Ultraviolet (UV) light including psoralen plus UV A has been 
used to ameliorate pruritus [36]. Pardo et al [37] reported that UVB 
decreased the number ofCD4+, CD8+, and CD2+ lymphocytes 
in patients responsive to therapy . Blauvelt et al [38] demonstrated 
demodex mites in six of six biopsies from patients with eosinophilic 
folliculitis, reported a response to prolonged administration of 
permethrin, and suggested that patients have a Th2 hypersensitivity 
to mites. Dust mite sensitivity, Th2 response with interleukin 
(IL)-4, pruritus, eosinophilia and IgE, and staphylococcal infections 
are also features of atopic dermatitis [39] . 
It is still not clear whether the pruritic papular eruption is one 
disease or many. A unifYing hypothesis is that during the course of 
HIV infection there is a shift in cellular immunity from a Th1 
immune response to a Th2 response, which may be modulated by 
IL-10 [9]. The Th1 response is associated with production of 
interferon-')I and IL-2, whereas the Th2 type of response is associ­
ated with IL-4, IL-5, IL-6, and IL-10. IL-4 and IL-5 induce IgE 
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production and eosinophilia, leading to atopy. Thus, patients with 
the pruritic papular eruption may have shifted their immune system 
to a Th2 atopic state. Of interest, HIV -positive patients with 
pruritic papular eruption have an increased incidence of autoanti­
bodies to bullous pemphigoid antigen, but the significance of this is 
unclear and it is perhaps related to mimicry to infectious agents 
[40] . 
Trigger factors for the atopic reaction in HIV patients' skin could 
include mites, insect saliva, staphylococcus, and possibly other 
factors. Staphylococcus colonization and infection is frequent in 
AIDS patients [27,41] and may produce toxins with the capability 
of acting as superantigens to stimulate T-cell proliferation [42]. 
Although elevated IgE levels to staphylococcal exotoxins of the 
skin have been reported in patients with atopic dermatitis, the role 
of staphylococcal superantigens in atopic dermatitis is more difficult 
to demonstrate [43]. 
AUTOIMMUNITY APPEARS DURING HIV INFECTION 
HIV gp 120 interacts with the T cell via the CD4 molecule of the 
T-cell receptor, the site of peptide antigen presentation and of 
superantigen binding [3,42]. As HIV buds from host cell mem­
branes, surtace proteins including human leukocyte antigen mole­
cules become part of the HIV virion coat [44]. Epitopes ofHIV are 
shared with major histocompatibility complex molecules and may 
also participate in graft versus host reactions to virally infected cells 
[45] . T-cell destruction may be mediated through apoptosis, pos­
sibly through mimicry between HIV gp 120 and the apoptosis­
mediating proteinfas [46]. A murine model for HIV autoimmunity 
has been proposed [47]. 
HIV-associated autoimmunity include s thrombocytopenia, poly­
myositis, vasculitis, DILS or Sjogren's syndrome, and bullous pemphi­
goid [45,48-51]. Psoriasis [52,53], alopecia areata, and vitiligo also 
occur [54]. Alopecia areata, vitiligo, and mucocutaneous candidiasis 
are associated with autoantibodies to melanocytes [55-57]. Although 
systemic lupus is rarely reported with HIV infection, photosensitivity 
dermatitis occurs [58,59]. 
KAPOSI'S SARCOMA (KS) 
AIDS was first recognized in 1981 when KS and Pneumocysitis carinii 
pneumonia occurred in previously healthy, young homosexual 
males [60,61]. KS had previously been known to occur in middle­
aged or elderly men, in immunocompromised individuals, and in 
equatorial Africa where Burkitt's lymphoma was endemic. Al­
though KS can be seen at any stage of HIV infection, it is AIDS­
defining by convention. 
KS is found in HIV -infected individuals with homosexual risk 
factors and is rarely reported in homosexual HIV - males or in 
HIV+ women with bisexual male partners [62]. KS in HIV+ 
homosexuals is decreasing in incidence, which supports the hypoth­
esis that there is a KS infectious agent [63]. Retroviral particles have 
been identified in KS lesions in patients with and without evidence 
ofHIV infection [64,65]. Herpes-like sequences have recently been 
identified in AIDS-associated KS [66]. 
Is KS truly a malignancy? What is the origin of the KS cell? Skin 
biopsy specimens from benign lesions or normal skin in AIDS 
homosexual patients frequently showed nonspecific, endothelial 
proliferation suggestive of KS even when no KS was ' clinically 
apparent (Duvic, unpublished data). HIV-infected cells produce 
cytokines and factors capable of stimulating widespread angioma­
tosis [67] . The origin of the KS cell has been suggested to be a 
primitive mesenchymal cell, an endothelial cell, or a dendritic 
dermal macrophage expressing factor XIIIa [67-69]. Tat, a viral 
product that up-regulates HIV expression, induces proliferation of 
KS cells in vitro [70]. Other growth factors expressed by KS cells 
that stimulate angiogenesis include oncostatin M, IL-1 and IL-6, 
platelet-derived growth factor, granulocyte-macrophage colony­
stimulating factor, and transforming growth factor [62,69]. Scatter 
factor, identified from human T-lymphotropic virus-II-conditioned 
medium, induces endothelial cells to differentiate into spindle-shaped 
KS-like cells in vitro and has recently been identified in KS lesions [71]. 
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The relation between HIV, KS, and psonaslS is intriguing, 
Kaposi's lesions have overlying epidennal hyperplasia, and psoriasis 
lesions show underlying endothelial proliferation. In KS and pso­
riasis, dendritic cells in the dennis appear to be infected by HIV 
[72) . KS may coexist with psoriasis in HIV + male homosexuals or 
may appear during the treatment of psoriasis with UV light [52]. 
HIV may be activated by UV light administration to transgenic 
mice [73]. Male mice transgenic for HIV Tat-Ltr transcripts 
develop KS-like lesions on the back in areas exposed to light and to 
trauma caused by other mice [74]. However, mice transgenic for 
whole HIV proviral sequences develop acral scaling and epidennal 
hyperplasia more like psoriasis [75]. Whether scatter factor may 
also play a role in psoriasis is not yet known. 
HlV-ASSOCIATED PSORIASIS VERSUS REITER'S 
SYNDROME 
Explosive psoriasis may be the first clinical manifestation of HIV 
infection. It may present with lesions characteristic of psoriasis 
subsets (vulgaris, guttate, pustular, acral, sebopsoriasis) appearing 
simultaneously in the same person [52,76,77]. Arthritis occurs in 
more than 30% of HIV + psoriatic patients, compared with 5% of 
historic controls, and is associated with human leukocyte antigen 
B27 and C7 creg antigens [78]. Reiter's syndrome may exist alone 
[79] . HIV + patients with guttate or psoriasis vulgaris skin lesions 
may develop incomplete or complete Reiter's syndrome [52,77]. 
This raises the question of the relation between the two "diseases" 
and the role of infectious triggers described in Reiter's syndrome. 
HIV infection and psoriasis have similar immunologic defects, and 
they may be synergistic [80] . 
The best-characterized infectious trigger for psoriasis is strepto­
coccus, which is associated with guttate disease [81]. However, 
psoriatic lesions may also be colonized with staphylococcus as well 
as other skin flora [82-84]. Staphylococcal infection and coloniza­
tion is common in HIV + patients with or without psoriasis 
[27,41,85,86]. Patients with exfoliative erythrodenna and psoriasis 
are invariably septic or bacteremic with staphylococcus, even in the 
absence of fever [86]. The role of bacterial or viral triggers and the 
possibility that streptococcus and staphylococcus act as superanti­
gens in psoriasis deserve further investigation. 
Pharmacology may help unravel the pathogenesis of psoriasis. 
Cyclosporin is effective, suggesting the importance of T-cell cyto­
kines [87,88) . However, it is paradoxic that psoriasis responds to 
immunosuppressive therapy and yet is aggravated by AIDS [52]. 
We have observed the clearing of psoriasis in end-stage AIDS when 
CD4 cells are absent [52]. Zidovudine (1200 mg/d) therapy was 
associated with improvement of psoriasis (but not arthritis) in 90% 
of HIV -infected patients [89] and in a third of HIV - psoriasis 
patients [90], but lower doses of zidovudine may not produce the 
same degree of benefit [76]. Although the mechanism of action is 
unknown, zidovudine has been shown to decrease keratinocyte 
proliferation in vitro [91] and may fimction as an inhibitor of DNA 
replication. Other antiviral therapies have not been reported to be 
of benefit in psoriatic HlV + patients. 
DOES UV LIGHT ADMINISTRATION ACTIVATE HIV IN 
PEOPLE? 
UVB and psoralen plus UV A are widely used for the treatment of 
HIV -associated psoriasis and papular pruritus/eosinophilic follicu­
litis [36,37,76,92]. HIV may be activated by UV radiation in vitro 
and in transgenic animals [93-97]. Three small pilot studies ad­
dressed the safety of UV administration in the setting of HIV 
infection and concluded that UV light had little or no effect in 
HIV-infected patients [98]. The CD4 counts of the patients were 
very low, and viral load was not monitored. UV light, especially 
psoralen plus UV A, which penetrates into the dennis, can be 
associated with clinical deterioration as well as viral activation, as 
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detennined by p24 antigen levels, especially in patients with 
elevated p24 antigens before treatment. * 
If UV light does activate HIV in skin, this may have profound 
implications for tanning and sun exposure in people infected with 
HlV. UV light could activate HIV by release of cytokines, DNA 
damage, or oxidative stress [96,99,100]. On the other hand, others 
have suggested that heat and radiation may actually inactivate HIV 
[101], and photopheresis has been reported to be of benefit in a 
limited number of patients [102]. The activation ofHlV in response 
to UV light remains one of the most interesting, and possibly 
important, controversies about HIV in the skin and is of great 
interest to dennatologists. 
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